A 50-year-old man with chronic myeloid leukemia in chronic phase fails therapy with both imatinib and dasatinib. Mutation analysis reveals the T315I mutation in the BCR-ABL kinase domain. Which tyrosine kinase inhibitor is effective against this specific mutation?
- A Ponatinib ✓
- B Bosutinib
- C Nilotinib
- D Flumatinib
Correct answer: A. Ponatinib
Explanation
The T315I mutation in the BCR-ABL kinase domain confers resistance to most first and second-generation TKIs. Ponatinib is a third-generation TKI specifically designed to overcome the T315I gatekeeper mutation. Nilotinib and bosutinib are second-generation TKIs with no activity against T315I.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.